• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Punctal plugs plus topical agent maximize eye relief

Article

Fort Lauderdale, FL—A dual treatment approach combining punctal plugs with use of topical cyclosporine ophthalmic emulsion 0.05% (Restasis, Allergan) affords dry eye sufferers greater improvement in their signs and symptoms than monotherapy with either modality alone, said Calvin W. Roberts, MD.

Dr. Roberts, clinical professor of ophthalmology, Weill Medical College of Cornell University, New York, reported the results of a parallel comparison study in which 30 consecutive patients with bilateral dry eye symptoms and 2+ conjunctival staining with lissamine green were randomly assigned to receive topical cyclosporine twice a day, punctal plugs to the lower lids only, or combination treatment. Responses were evaluated after 1, 3, and 6 months by assessing Schirmer test results (5 minutes with anesthesia), conjunctival staining scores, and frequency of use of artificial tears for symptom relief. He presented the results at the Association for Research in Vision and Ophthalmology annual meeting here earlier this month.

After just 1 month, punctal plugs were associated with marked improvement in Schirmer scores and decreased frequency of artificial tear use, but that intervention had little effect on conjunctival staining. Onset to efficacy took longer with cyclosporine monotherapy, but all three measures of efficacy eventually improved with its use. However, patients in the combination group enjoyed the benefits of both modalities with improvements that occurred early and that were equal or superior to those associated with either of the monotherapies.

Mean lissamine green conjunctival staining scores in the three groups ranged from 2 to 2.3 at baseline (possible score range, 0 to 4). All groups showed a modest benefit after 1 month (mean change range, –0.2 to –0.3), and there was no further improvement throughout the course of the study in the patients using punctal plugs. However, patients using cyclosporine alone or in combination with punctal plugs achieved greater reductions in conjunctival staining after 3 months and further benefit by study conclusion when mean changes from baseline were –0.9 and –1, respectively.

Mean frequency of artificial tear instillation at baseline ranged from 5.5 to 6.0 times daily across the three treatment groups. By 1 month, patients who had punctal plugs placed reduced their usage by about two instillations a day whether or not they also were using cyclosporine whereas patients using cyclosporine monotherapy had minimal change (–0.6).

Related Videos
© 2024 MJH Life Sciences

All rights reserved.